Chapter 111

## Abstract

Abstract

1. Xanthine oxidoreductase (XOR) catalyzes the final reactions of the purine catabolic pathway, oxidizing hypoxanthine to xanthine and xanthine to uric acid. Inherited deficiency of the enzyme results in xanthinuria (MIM 278300), which is usually clinically mild or asymptomatic. Precipitation of xanthine in the urinary tract or muscle may give rise to the most common symptoms, urolithiasis (with secondary renal damage) and muscle pain. Biochemically the disease is characterized by low uric acid and elevated xanthine in plasma and urine. Xanthinuria is an autosomal recessive disease.

2. In addition to hypoxanthine and xanthine, XOR oxidizes adenine, 6-mercaptopurine, and allopurinol; a number of pyrimidines, aldehydes, and pterins are also substrates. Under physiological conditions, XOR functions mainly as a dehydrogenase, with NAD+ as the cosubstrate, but it can be converted into an oxidase, which utilizes molecular oxygen as the cosubstrate and produces hydrogen peroxide and superoxide. The enzyme may also form nitric oxide by reducing nitrite or by cleaving nitrosothiols. The Km values of both the dehydrogenase and the oxidase for the purine substrates are in the range of 10−6–10−5 M.

3. Reversible conversion of xanthine dehydrogenase into oxidase occurs by sulfhydryl group oxidation, which results in loss of the NAD+ binding site. Irreversible proteolytic conversion into oxidase occurs upon enzyme purification, tissue ischemia, or treatment with proteolytic enzymes. In cell and tissue extracts, 7–35 percent of total enzyme activity is accounted for by the oxidase. Inactive enzyme forms include desulfo-XOR and demolybdo-XOR.

4. The human XOR gene is located on chromosome 2p22, spans at least 60 kb, and consists of 36 exons and 35 introns. The cDNA for human xanthine dehydrogenase corresponds to a polypeptide of 1333 amino acids, with a predicted molecular weight of ∼146 kDa. Purified human XOR is a dimer of two identical subunits of ∼150 kDa. Each subunit consists of three domains, cleavable by proteolysis but remaining associated under nondenaturing conditions. The N-terminal 20-kDa domain contains two nonidentical Fe-S centers, the middle 40-kDa domain contains an FAD center, and the C-terminal 85-kDa domain contains molybdenum bound to a cofactor. Catalysis is initiated by the transfer of two electrons to the Mo(VI) atom, followed by intramolecular electron transfer to the Fe-S centers and finally to FAD, which is then oxidized by either NAD+ or oxygen. Allopurinol inhibits the enzyme after being converted into oxypurinol, which binds tightly to the molybdenum center.

5. Enzyme activity, immunoreactive protein, and mRNA of XOR are abundantly expressed in human proximal small intestine and liver; low activity is inconsistently present in kidney and lung. Immunohistochemistry shows expression in intestinal epithelial cells and hepatocytes, faintly in other organs' capillary endothelial cells. Resting mammary epithelium contains enzyme protein, which increases during lactation. No activity, protein, or mRNA can be detected in human myocardium or brain. Basal expression is increased during hypoxia by posttranslational mechanisms. Hyperoxia suppresses enzyme activity by inactivation of the enzyme protein and by inhibition of transcription. Several cytokines (e.g., γ-interferon) activate transcription. Nitric oxide donors and NO itself suppress XOR activity.

6. Xanthine oxidase has been ascribed a role in ischemia-reperfusion damage. Hypoxanthine and xanthine accumulate during ischemia, and a burst of oxidants is produced upon reperfusion. This phenomenon, and the attendant tissue injury, can be alleviated by allopurinol or inactivation of XOR by tungsten pretreatment. Clinical trials giving allopurinol to patients undergoing coronary bypass surgery support the role of XOR in reperfusion injury, but it is unlikely that conversion of dehydrogenase to oxidase is required. The product of XOR, uric acid, has been proposed to be a physiological antioxidant.

7. Human aldehyde oxidase is closely related to XOR but functions only as an oxidase. The predicted amino acid sequences are 49 percent homologous; both enzymes contain similar molybdenum, FAD, and Fe-S centers; and the intron-exon structures are almost identical, but the regulatory 5′-flanking regions are different. The substrate specificity of the two enzymes overlap widely, N1-methylnicotinamide being relatively specific for aldehyde oxidase and hypoxanthine or xanthine for XOR. Aldehyde oxidase is expressed at a high level in the liver and lung but at a low level in the intestine.

8. Hereditary xanthinuria (MIM 278300) results from a genetic deficiency of XOR (type I) or both XOR and aldehyde oxidase (type II). The two types are clinically similar, but whereas type I patients can metabolize allopurinol, type II patients cannot. Over 100 cases have been reported, roughly equally divided between type I and type II. Less than half of the patients have symptoms, which are caused by deposition of xanthine in the urinary tract, resulting in hematuria or renal colic and rarely in acute renal failure or chronic complications related to urolithiasis. Muscle pains due to xanthine deposition occur in a minority of cases. Plasma uric acid is below 5 μM and plasma xanthine over 10 μM. The urinary excretion of uric acid is low or unmeasurable and that of xanthine is elevated. Treatment consists of a low-purine diet and high fluid intake.

9. Xanthinuria is inherited in an autosomal recessive manner. A single-nucleotide mutation responsible for type I disease has been characterized in four Japanese patients and results in a nonsense mutation. In type II xanthinuria, the mutation may be not in the structural gene of either XOR or aldehyde oxidase but possibly in the mechanism responsible for inserting the essential sulfur atom into the active centers of both enzymes.

Sign in to your MyAccess profile while you are actively authenticated on this site via your institution (you will be able to verify this by looking at the top right corner of the screen - if you see your institution's name, you are authenticated). Once logged in to your MyAccess profile, you will be able to access your institution's subscription for 90 days from any location. You must be logged in while authenticated at least once every 90 days to maintain this remote access.

Ok

## Subscription Options

### OMMBID Full Site: One-Year Subscription

Connect to the full suite of OMMBID content including new and revised chapters that reflect the latest research, image galleries, clinical phenotypes, and more.